genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2012
Benign prostatic hyperplasia
News
EC Follows FDA and Approves Lilly’s Erectile Dysfunction Drug for BPH
Cancer
Tolmar Grants Astellas European Rights to Prostate Cancer Therapy in New Territories
News
Recordati Pays Nymox €10M Up Front for Rights to Late-Stage BPH Drug in 81 Countries
News
GSK’s BPH Therapy Receives European Clearance
News
Spectrum Ditches Mid-Stage BPH Therapy
Industry News
BioXell Welcomes Cosmo’s Proposed $40.9M Acquisition
News
Recordati Inks Marketing Deals for BPH Therapy in Italy and South Africa
News
Almirall to Commercialize Recordati’s BPH Drug in Spain
News
Sanofi-Aventis to Commercialize AEterna Zentaris’ Late-Stage BPH Drug in the U.S.
News
AEterna Zentaris Reclaims Cetrorelix Rights for All Indications
1
2
Page 1 of 2
Scroll Up
Scroll Up
